濮阳东方医院治阳痿技术(濮阳东方男科怎么样) (今日更新中)

MOSCOW, Oct. 3 (Xinhua) -- A Soyuz-2.1B rocket carried a Glonass-M navigation satellite into orbit early Monday after a two-day delay caused by high winds, a Russian Space Forces spokesman said."The launch of the booster rocket is as scheduled. The satellite Glonass-M was put into the orbit under control at 03:55 Moscow time (2355 GMT on Sunday)," said Colonel Alexei Zolotukhin.Zolotukhin told reporters that the rocket was launched at 0:15 Moscow time (2015 GMT, Sunday) from the Plesetsk Space Center in northern Russia.The Russian Space Forces said the launch was initially scheduled for Saturday but was postponed due to high winds.Glonass is the Russian equivalent of the U.S. Global Positioning System (GPS), which is designed for both military and civilian use. The system requires 24 operational and 2-3 reserve satellites in orbit to ensure global coverage.In December 2010, a malfunction of the booster resulted in a loss of three Glonass satellites.

BEIJING, Dec. 24 (Xinhua) -- Renowned China economist Li Yining said Saturday that adjusting the structure of China's economy is a "matter of life and death" while the structure of GDP is more important than its size.The focus of the country's economic structure adjustment now should be transforming the dual structure in the urban and rural economy, which causes the widening income gaps between urban and rural residents, Li said at the China Economic Forum.He also noted that the key to stimulating domestic demand is to raise the workers' wages.With the external demand waned, the Chinese government has attempted to turn to domestic consumers to take up the slack. The country vows to expand domestic demand next year and increase residents' income, especially for disadvantaged groups.However, Li said raising household income is not enough and the government also needs to improve its social security system as well as increase construction of affordable houses and public rental houses.The country plans to begin construction or renovation on at least 7 million housing units for low-income groups next year, Minister of Housing and Urban-Rural Development Jiang Weixin said Friday.

SAN FRANCISCO, Dec. 9 (Xinhua) -- Apple on Friday suffered a major setback in its global patent war, as a German court ruled over its copyright infringement battle in favor of Motorola Mobility.The German court ruled that Apple's iPhone and iPad infringe a Motorola patent and issued an injunction banning the import of iPhones and 3G-capable iPads into Germany.The dispute, one of Apple's several patent lawsuits around the world, is over a Motorola patent essential to GPRS. Motorola has been negotiating with Apple over licensing terms and conditions since 2007, and it will continue its efforts to resolve its global patent dispute as soon as practicable, said Motorola Mobility in a statement on Friday."We're going to appeal the court's ruling right away. Holiday shoppers in Germany should have no problem finding the iPad or iPhone they want," an Apple spokesman told tech news site AllThingsD.Apple is not too concerned about losing out in the Christmas shopping season as it has plenty of iPhones and iPads in Germany already, AllThingsD cited unidentified sources as saying.The ruling is against Apple's European sales company and only impacts its products sold in Germany. The German court also ruled that Motorola is entitled to a damages award.Apple can appeal the ruling to a higher court and request a stay of the injunction, according to a blog post of Florian Mueller, a U.S. patent expert who has been closely following patent lawsuits in the mobile industry.Mueller said should Apple make the appeal but the court declines the stay, Motorola must post a 100 million euro (around 134 million U.S. dollars) bond before the court will enforce the injunction.In August, Apple also filed a suit in Germany over the design of Motorola's tablet Xoom, which runs Google's Android system. But Apple did not make it clear whether it will seek to block the sales of Xoom in Europe.Also on Friday, Samsung won an appeal from the Australian High Court overturning a previous Apple victory that effectively banned Samsung from selling its Galaxy Tab in Australia.Based on claims of infringing Apple's patents, the Cupertino, California-based tech giant has been seeking court order to block Samsung's Galaxy line of mobile devices around the world.A German court issued an injunction in August, blocking Samsung from selling its Galaxy Tab 10.1 tablets across all European Union members, except for the Netherlands.On Thursday, Apple said it will appeal a San Jose, California judge's refusal to ban sales of Samsung 4G smartphones and Galaxy Tab 10.1 tablets in the United States.

WASHINGTON, Oct. 13 (Xinhua) -- U.S. researchers have corrected sickle cell disease in adult laboratory mice that had been bred to have the inherited blood disorder by activating production of a special blood component, according to a study published online Thursday in the journal Science.Sickle cell disease results from an abnormality in hemoglobin, the protein found in red blood cells that is responsible for transporting oxygen throughout the body. People living with sickle cell disease have two copies of an altered gene that produces sickle hemoglobin instead of normal adult hemoglobin. Sickle hemoglobin changes shape after releasing its oxygen, causing the red blood cell to become stiff, misshapen and sticky, and slowing blood flow to tissues. This process damages organs and causes pain.The study tested a new approach to increasing the production of a third form of hemoglobin -- fetal hemoglobin. Production of fetal hemoglobin predominates before birth, but turns off thereafter as adult hemoglobin production takes over. People with sickle cell disease are unable to make normal adult hemoglobin, and instead make sickle hemoglobin starting in infancy.An elevated level of fetal hemoglobin within the red blood cell reduces the tendency of sickle hemoglobin to change the shape of red blood cells. Considerable research has shown that the drug hydroxyurea increases production of fetal hemoglobin and reduces the number of pain crises and other complications of sickle cell disease in adults and children. However, not all patients respond well to hydroxyurea, and adverse side effects are a concern.The current study explores a more targeted approach to increasing fetal hemoglobin production. It builds upon earlier studies that discovered a protein called BCL11A normally suppresses the production of fetal hemoglobin soon after birth. The researchers viewed the BCL11A protein as a target for therapy and decided to see what would happen if they blocked production of the protein.The paper details how the research team silenced the mouse gene that produces the BCL11A protein in mice with sickle cell disease. Silencing the gene turned off production of the BCL11A protein and allowed the adult mice to continue to produce fetal hemoglobin. It appears to have eliminated disease symptoms without affecting other aspects of blood production."This discovery provides an important new target for future therapies in people with sickle cell disease," said Susan Shurin, acting director of the U.S. National Heart, Lung, and Blood Institute, which co-funded the study. "More work is needed before it will be possible to test such therapies in people, but this study demonstrates that the approach works in principle."Approximately 100,000 Americans live with sickle cell disease. It is most prevalent in people of African, Hispanic, Mediterranean, and Middle Eastern descent. There is no widely available cure for sickle cell disease. Bone marrow transplants have cured some patients, but the treatment is not without risk and most patients do not have relatives who can donate compatible and healthy bone marrow to them.

来源：资阳报